Zydus Lifesciences (ZYDUSLIFE) Stock Overview
Engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
ZYDUSLIFE Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Zydus Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹982.75 |
| 52 Week High | ₹1,324.30 |
| 52 Week Low | ₹795.00 |
| Beta | 0.49 |
| 1 Month Change | 2.62% |
| 3 Month Change | 18.18% |
| 1 Year Change | -17.11% |
| 3 Year Change | 177.10% |
| 5 Year Change | 165.64% |
| Change since IPO | 11,226.47% |
Recent News & Updates
Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jul 06
Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Larger Dividend Than Last Year At ₹11.00
Jun 22Recent updates
Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jul 06Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Larger Dividend Than Last Year At ₹11.00
Jun 22Zydus Lifesciences (NSE:ZYDUSLIFE) Is Paying Out A Larger Dividend Than Last Year
May 23If EPS Growth Is Important To You, Zydus Lifesciences (NSE:ZYDUSLIFE) Presents An Opportunity
Mar 30Does Zydus Lifesciences (NSE:ZYDUSLIFE) Have A Healthy Balance Sheet?
Mar 12There's No Escaping Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Muted Earnings
Feb 24Zydus Lifesciences Limited Just Recorded A 12% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 09Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Might Deserve Your Attention Today
Dec 16These 4 Measures Indicate That Zydus Lifesciences (NSE:ZYDUSLIFE) Is Using Debt Safely
Nov 30
Innovation In Healthcare And Wellness Propels This Company's Global Growth Journey
Focus on innovation and differentiated products in India and international markets aims to drive revenue and enhance net margins.Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 15Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Shareholder Returns
| ZYDUSLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.0% | 2.4% | -0.1% |
| 1Y | -17.1% | 10.4% | -2.5% |
Return vs Industry: ZYDUSLIFE underperformed the Indian Pharmaceuticals industry which returned 10.4% over the past year.
Return vs Market: ZYDUSLIFE underperformed the Indian Market which returned -2.5% over the past year.
Price Volatility
| ZYDUSLIFE volatility | |
|---|---|
| ZYDUSLIFE Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: ZYDUSLIFE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ZYDUSLIFE's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 27,917 | Sharvil Patel | zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.
Zydus Lifesciences Limited Fundamentals Summary
| ZYDUSLIFE fundamental statistics | |
|---|---|
| Market cap | ₹988.88b |
| Earnings (TTM) | ₹45.26b |
| Revenue (TTM) | ₹232.42b |
Is ZYDUSLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYDUSLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹232.42b |
| Cost of Revenue | ₹65.38b |
| Gross Profit | ₹167.03b |
| Other Expenses | ₹121.78b |
| Earnings | ₹45.26b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 14, 2025
| Earnings per share (EPS) | 44.97 |
| Gross Margin | 71.87% |
| Net Profit Margin | 19.47% |
| Debt/Equity Ratio | 12.0% |
How did ZYDUSLIFE perform over the long term?
See historical performance and comparisonDividends
Does ZYDUSLIFE pay a reliable dividends?
See ZYDUSLIFE dividend history and benchmarks| Zydus Lifesciences dividend dates | |
|---|---|
| Ex Dividend Date | Jul 25 2025 |
| Dividend Pay Date | Sep 11 2025 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 55 days |
Does ZYDUSLIFE pay a reliable dividends?
See ZYDUSLIFE dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/17 19:37 |
| End of Day Share Price | 2025/07/17 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zydus Lifesciences Limited is covered by 66 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |